OXFORD, UK and DRESDEN, GERMANY--(Marketwire - September 15, 2011) - Mirada Medical and ABX-CRO announce today that they have formalised an agreement under which ABX-CRO will utilise Mirada’s most advanced multi-modality imaging applications to deliver greater efficiency and more reliable results in clinical trials in oncology and neurosciences.
Mirada’s products, which have been developed for clinical use and are cleared by the FDA, are uniquely suited to usage in clinical trials because they support unlimited patient timepoints for follow-up assessment of CT, MR, PET or SPECT or any hybrid combination of the two. The applications incorporate native support for standard protocols such as RECIST and PERCIST, and can be modified to support the specific protocols of any given trial. Complex findings and results may be automatically sent to the trial-specific database in a pre-defined trial specific format, thereby reducing time and avoiding errors which may be caused when working through spread sheets or paper based systems. This combination of advanced quantification techniques and configurable analysis protocol is critical to improving consistency and efficiency when following a patient through a clinical trial over a number of days, months or years.
ABX-CRO provides comprehensive development services for imaging biomarkers, and implements advanced PET and SPECT imaging solutions for therapy trials. Introducing advanced molecular imaging into late-stage drug development, ABX-CRO offers the pharmaceutical industry a wealth of quantitative endpoints, mechanistically evidencing drug effects or predicting clinical outcome. Mirada’s advanced imaging applications allow ABX-CRO to further develop their market adopting more powerful analysis techniques at a larger scale.
Mirada Medical Chief Executive Hugh Bettesworth welcomes the new agreement
“We are excited to be working with ABX-CRO who we consider to be one of the most innovative companies working in clinical trials today. By combining their knowledge of the trials industry with Mirada’s stunning technologies to enable software assisted multi-modality and novel molecular image quantification over successive patient follow ups, we believe we can offer new levels of productivity and data compliance in cancer trials”.
Dr. Andreas Kluge, General Manager and founder of ABX-CRO states
“Mirada combines mature cutting-edge technology, with the ability and flexibility to provide special solutions for new requirements, allowing us to comprehensively address most standard and non-standard analytical problems with a single solution. We feel that Mirada and ABX-CRO are natural partners in their mission to make quantitative molecular imaging a reality not only in clinical medicine but also in late-stage drug development.
About Mirada Medical
Mirada Medical is an internationally recognized brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.
Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.
Mirada was originally spun out of the University of Oxford. The company’s technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.
Mirada’s products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada’s applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis.
Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada’s powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at tumor board.
For more information, visit www.mirada-medical.com
About ABX-CRO
ABX-CRO, as an independent full service clinical research organisation, represents more than 12 years of comprehensive drug development services in nuclear medicine. Integrated development of new PET & SPECT biomarkers,stand-alone PET/SPECT imaging solutions in the context of therapeutic trials, and diagnostic imaging solutions (PET microdosing & dose finding studies) are our key activities.
ABX-DIRECT (Diagnostic Image Remote Exchange for Clinical Trials), the 21 CFR part 11 compliant cutting-edge tool specifically developed for the needs of global clinical research will enhance the value of this cooperation for the customers of Mirada and ABX-CRO.
ABX-DIRECT enables secure transfer of DICOM images to the ABX-CRO image data server directly from PACS or through conventional file upload. On-the-fly anonymisation is carried out in accordance with HIPAA requirements.
ABX-CRO has retained a strong focus in oncology and neuroscience, the indications that most utilise imaging parameters for their endpoints. Our customers include both the pharmaceutical and the biotechnology industries.
For more information, visit www.abx-cro.com
Mirada Medical, ABX Release: http://hugin.info/143183/R/1546676/474551.pdf
For more information, please contact:
Mirada Medical
US/Worldwide: Robert Ripley
tel: (440) 591-8638
Insource Communications
rripley@insourceinc.com
enquiries@mirada-medical.com
www.mirada-medical.com
ABX
Contact:
Dr. Andreas Kluge, General Manager
tel: +49 (0) 351 214 44 10
